<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-32717" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>ANCA-Associated Vasculitis</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Qasim</surname>
            <given-names>Abdallah</given-names>
          </name>
          <aff>Creighton University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Jayesh B.</given-names>
          </name>
          <aff>University of Iowa Hospitals and Clinics</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Abdallah Qasim declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Jayesh Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>31</day>
          <month>8</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-32717.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Antineutrophil cytoplasmic antibody (ANCA)&#x02013;associated vasculitides are a heterogeneous group of rare autoimmune conditions that cause inflammation of blood vessels with various manifestations. The 3 main ANCA&#x02013;associated vasculitides are granulomatosis with polyangiitis, microscopic polyangiitis, and eosinophilic granulomatosis with polyangiitis. All the ANCA&#x02013;associated vasculitides affect small vessels, such as capillaries, venules, and arterioles, and have a myriad of clinical manifestations, some overlapping and some independent of each other. Granulomatosis with polyangiitis and microscopic polyangiitis&#x000a0;are similar in their clinical presentations and treatment protocols. Understanding the role of antineutrophil cytoplasmic antibodies and accurately interpreting test results are essential for effectively diagnosing and managing these diseases.&#x000a0;This activity&#x000a0;discusses the clinical evaluation and management of ANCA&#x02013;associated vasculitides and highlights the role of an interprofessional team in treating patients with these conditions.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the pathogenesis of antineutrophil cytoplasmic antibody&#x02013;associated vasculitides.</p></list-item><list-item><p>Implement appropriate diagnostic protocols, including serological tests and tissue biopsies, to confirm the diagnosis of ANCA-positive vasculitis.</p></list-item><list-item><p>Compare the management options available for antineutrophil cytoplasmic antibody&#x02013;associated vasculitides.</p></list-item><list-item><p>Collaborate with a multidisciplinary team, including rheumatologists, nephrologists, pulmonologists, and pharmacists, to optimize patient care.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=32717&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=32717">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-32717.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Antineutrophil cytoplasmic antibody (ANCA)&#x02013;associated vasculitides are a heterogeneous group of rare autoimmune conditions that cause inflammation of blood vessels with various manifestations.&#x000a0;This group includes&#x000a0;3 main diseases&#x02014;granulomatosis with polyangiitis (GPA), formerly known as Wegener granulomatosis; eosinophilic granulomatosis with polyangiitis (EGPA), previously known as Churg-Strauss syndrome; and&#x000a0;microscopic polyangiitis (MPA). Other ANCA-associated diseases&#x000a0;include drug-induced vasculitis and renal-limited vasculitis.</p>
        <p>Please see StatPearls' companion resources, "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/76416">Granulomatosis with Polyangiitis</ext-link>," "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/19543">Eosinophilic Granulomatosis with Polyangiitis</ext-link>,"&#x000a0;"<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/25111">Microscopic Polyangiitis</ext-link>," and "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/22288">Rapidly Progressive Glomerulonephritis</ext-link>,"&#x000a0;for further information.</p>
      </sec>
      <sec id="article-32717.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>The link between&#x000a0;the clinical syndromes, such as GPA, EGPA, and MPA, and ANCA was established in 1988 when the&#x000a0;sera&#x000a0;of patients with crescentic glomerulonephritis were found to bind to&#x000a0;neutrophils&#x000a0;in 2 recognizable&#x000a0;patterns&#x02014;perinuclear&#x000a0;or diffusely throughout the cytoplasm. Further examination revealed that these patterns correlated with 2 types of antibodies&#x02014;perinuclear staining (P-ANCA) corresponds primarily with neutrophil myeloperoxidase (MPO) and cytoplasmic staining (C-ANCA) primarily against neutrophil proteinase 3 (PR3).<xref ref-type="bibr" rid="article-32717.r1">[1]</xref><xref ref-type="bibr" rid="article-32717.r2">[2]</xref><xref ref-type="bibr" rid="article-32717.r3">[3]</xref>&#x000a0;The aforementioned&#x000a0;clinical syndromes are typically positive for either of those antibodies.</p>
        <p>ANCA serology is positive in about 90% of GPA and MPO cases, whereas it is positive in about 30% of EGPA cases.<xref ref-type="bibr" rid="article-32717.r4">[4]</xref>&#x000a0;Anti-PR3 antibodies are about 90% sensitive for GPA.<xref ref-type="bibr" rid="article-32717.r5">[5]</xref><xref ref-type="bibr" rid="article-32717.r6">[6]</xref>&#x000a0;Although sensitive and specific for GPA, ANCA positivity has also been noted in 15% to 20% of patients with systemic lupus erythematosus, especially those with lupus nephritis, and other autoimmune conditions.<xref ref-type="bibr" rid="article-32717.r7">[7]</xref></p>
        <p>C-ANCA with extranuclear cytoplasmic staining is 90% PR3-reactive and 10% MPO-reactive; P-ANCA with staining around the nucleus is 90% MPO-reactive and 10% PR3-reactive.<xref ref-type="bibr" rid="article-32717.r8">[8]</xref></p>
      </sec>
      <sec id="article-32717.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>The peak onset of ANCA-associated vasculitides typically occurs between 45&#x000a0;and 60, with a slight male prevalence that varies by specific condition. Among the 3 main types of ANCA-associated vasculitides, GPA is the most common, followed by MPA and EGPA. Higher incidence rates are&#x000a0;observed in colder regions. The prevalence of GPA in European and American populations is about 120 to 140 per million.<xref ref-type="bibr" rid="article-32717.r9">[9]</xref><xref ref-type="bibr" rid="article-32717.r10">[10]</xref>&#x000a0;A national study in the Netherlands found that 167 patients (73%) were diagnosed with GPA, 54 patients (24%) with MPA, and 9 patients (4%) with EGPA. This distribution is similar to other European registries.<xref ref-type="bibr" rid="article-32717.r11">[11]</xref>&#x000a0;</p>
        <p>Globally, the estimated incidence rates are 130 per million for GPA, 20 per million for MPA, and 1 to 3 per million for EGPA. GPA is more common than MPA in populations of European descent, whereas MPA is more common in China and Japan.<xref ref-type="bibr" rid="article-32717.r12">[12]</xref></p>
      </sec>
      <sec id="article-32717.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Several complex interactions involving genetics and microbes have been implicated in the etiology of GPA. ANCA is responsible for inflammation in ANCA-associated vasculitis. Defective immune-regulatory responses to environmental insults, such as infection or autoantigens,&#x000a0;can lead to excessive production of cytokines, ultimately resulting in the formation of inflammatory granulomatous vascular lesions.<xref ref-type="bibr" rid="article-32717.r13">[13]</xref></p>
        <p>Understanding the 2 primary ANCA types&#x02014;anti-PR3 and anti-MPO&#x02014;is essential for comprehending the disease process. Some studies suggest that the type of antibody may have better prognostic value than the clinical syndrome patterns themselves. ANCA in GPA typically reacts with PR3, a serine proteinase prevalent in neutrophil granulocytes. ANCA activates neutrophils, which leads to increased adherence to endothelium and induces their degranulation, which can damage endothelial cells.&#x000a0;In GPA cases, anti-PR3 is positive in about 75% of&#x000a0;cases; anti-MPO antibody is positive in about 10% of&#x000a0;cases; fewer than 10% are ANCA-negative.<xref ref-type="bibr" rid="article-32717.r6">[6]</xref>&#x000a0;With MPA, anti-MPO is positive in about 70% of&#x000a0;cases.<xref ref-type="bibr" rid="article-32717.r12">[12]</xref></p>
        <p>Neutrophils from patients with GPA are more likely to produce neutrophil extracellular traps and have lower DNAse I activity, leading to decreased NET clearance. Neutrophil extracellular traps are composed of decondensed chromatin and intracellular granules that capture cell components.<xref ref-type="bibr" rid="article-32717.r7">[7]</xref><xref ref-type="bibr" rid="article-32717.r14">[14]</xref>&#x000a0;ANCA&#x000a0;binds to neutrophils, leading to degranulation, reactive oxygen species, adhesion to endothelial cells, and secretion of pro-inflammatory cytokines, especially&#x000a0;interleukin-8.<xref ref-type="bibr" rid="article-32717.r6">[6]</xref>&#x000a0;Although neutrophils are integral to innate immunity, adaptive immunity responses are also noteworthy. B-cells specific to PR3 are correlated with disease activity and risk of relapse.<xref ref-type="bibr" rid="article-32717.r15">[15]</xref></p>
        <p>Genetic associations in GPA include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>A defective allele for alpha-1 antitrypsin</p>
          </list-item>
          <list-item>
            <p>Cytotoxic T-lymphocyte&#x02013;associated protein 4 (CTLA-4), which is involved in T-cell activation</p>
          </list-item>
          <list-item>
            <p>PR3 gene</p>
          </list-item>
          <list-item>
            <p>Major histocompatibility complex, class II, DP alpha-1 (HLA-DP) gene</p>
          </list-item>
          <list-item>
            <p>Certain types of FC gamma receptor III b on the surface of neutrophils and macrocytes&#x000a0;or monocytes&#x000a0;<xref ref-type="bibr" rid="article-32717.r16">[16]</xref></p>
          </list-item>
        </list>
        <p><bold>Infections:</bold> In addition to the initiation and exacerbation of the vasculitic process, infectious agents have also been known to modulate the clinical phenotype of the disease.&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Bacterial: Colonization with&#x000a0;<italic toggle="yes">Staphylococcus aureus</italic>&#x000a0;has been hypothesized as an initiating factor for inflammation observed in GPA because it is associated with the release of neutrophil extracellular traps.<xref ref-type="bibr" rid="article-32717.r14">[14]</xref></p>
          </list-item>
          <list-item>
            <p>Viral: Association with various viruses, including hepatitis C virus, cytomegalovirus, Epstein-Barr virus, and parvovirus, have been reported.<xref ref-type="bibr" rid="article-32717.r17">[17]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Drugs Linked to ANCA-Associated Vasculitis</bold>
</p>
        <p>Certain medications can induce ANCA-associated vasculitis, typically manifesting as rapidly progressive glomerulonephritis (RPGN). Specifically, a high MPO titer is common. Levamisole, which is often found in contaminated cocaine,&#x000a0;can cause the elevation of both anti-MPO&#x000a0;and anti-PR3 antibodies, along with other autoantibodies, skin lesions, and arthralgias. Treatment is the same as that of other ANCA-associated RPGN cases, but possibly with shorter induction, and prolonged maintenance is typically unnecessary. Once the drug is discontinued, relapse is uncommon, unlike GPA/MPA. The most common offending medications include these:</p>
        <list list-type="bullet">
          <list-item>
            <p>Hydralazine</p>
          </list-item>
          <list-item>
            <p>Propylthiouracil and methimazole</p>
          </list-item>
          <list-item>
            <p>Allopurinol</p>
          </list-item>
          <list-item>
            <p>Sulfasalazine</p>
          </list-item>
          <list-item>
            <p>Minocycline</p>
          </list-item>
          <list-item>
            <p>Penicillamine</p>
          </list-item>
          <list-item>
            <p>Rifampicin</p>
          </list-item>
          <list-item>
            <p>Aminoguanidine</p>
          </list-item>
          <list-item>
            <p>Sofosbuvir</p>
          </list-item>
          <list-item>
            <p>Anti-tumor necrosis factor-alpha (TNF-&#x003b1;) therapy for rheumatoid arthritis and ankylosing spondylitis&#x000a0;<xref ref-type="bibr" rid="article-32717.r18">[18]</xref></p>
          </list-item>
        </list>
        <p><bold>Double-Positive Antibody Disease</bold>&#x000a0;</p>
        <p>Also called dual antibody disease, this type of crescentic glomerulonephritis is associated with a positive ANCA and anti-GBM antibody. Some studies indicate that 10% to 50% of patients with anti-GBM disease have detectable ANCA, typically anti-MPO. In contrast, up&#x000a0;to 10% of patients with ANCA-associated vasculitis also have circulating anti-GBM antibodies.<xref ref-type="bibr" rid="article-32717.r19">[19]</xref>&#x000a0;Generally, the positive ANCA precedes the anti-GBM antibodies;&#x000a0;therefore, it is postulated that ANCA leads to the anti-GBM antibodies by exposing epitopes on the GBM. Renal manifestations follow an anti-GBM pattern, whereas systemic symptoms are similar to those of ANCA vasculitis.<xref ref-type="bibr" rid="article-32717.r20">[20]</xref><xref ref-type="bibr" rid="article-32717.r21">[21]</xref>&#x000a0;This double-positive characteristic comes into play&#x000a0;during treatment selection.<xref ref-type="bibr" rid="article-32717.r15">[15]</xref><xref ref-type="bibr" rid="article-32717.r22">[22]</xref></p>
      </sec>
      <sec id="article-32717.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Immunohistology typically reveals few or no immunoglobulin and complement deposits, so these conditions are called pauci-immune vasculitides.</p>
        <list list-type="bullet">
          <list-item>
            <p>Granulomatosis with polyangiitis: A lung tissue biopsy shows evidence of vasculitis and necrotizing granuloma formation, which are characteristic of this disease. However, kidney biopsy&#x000a0;does not show granulomas.</p>
          </list-item>
          <list-item>
            <p>Microscopic polyangiitis: Biopsy shows capillaritis without granuloma formation, leukocytoclastic changes, and crescentic glomerulonephritis in the kidneys.</p>
          </list-item>
          <list-item>
            <p>Eosinophilic granulomatosis with polyangiitis: Biopsy shows necrotizing vasculitis with eosinophilic infiltrates and eosinophilic granulomas.<xref ref-type="bibr" rid="article-32717.r23">[23]</xref><xref ref-type="bibr" rid="article-32717.r24">[24]</xref><xref ref-type="bibr" rid="article-32717.r25">[25]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-32717.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Patients with ANCA vasculitides typically present with symptoms such as fatigue, fever, and weight loss. However, these conditions can manifest in various clinical syndromes, as outlined below.</p>
        <p>
<bold>Granulomatosis With Polyangiitis</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>GPA typically involves the upper and lower respiratory tracts&#x000a0;and&#x000a0;kidneys.</p>
          </list-item>
          <list-item>
            <p>Upper respiratory tract symptoms include bloody nasal discharge, nasal ulceration,&#x000a0;sinusitis,&#x000a0;and chronic otitis media. Damage of the nasal cartilage can&#x000a0;cause the characteristic saddle&#x000a0;nose deformity.</p>
          </list-item>
          <list-item>
            <p>Symptoms of the lower respiratory tract secondary to lung nodules&#x000a0;and&#x000a0;alveolar hemorrhage sometimes can be severe and fatal. Rarely it can cause tracheal stenosis.</p>
          </list-item>
          <list-item>
            <p>Renal involvement can cause&#x000a0;rapidly progressive renal failure. The patient can present with&#x000a0;high blood pressure, new-onset proteinuria, and active urinary sediments (hematuria, leukocyturia).<xref ref-type="bibr" rid="article-32717.r26">[26]</xref><xref ref-type="bibr" rid="article-32717.r27">[27]</xref><xref ref-type="bibr" rid="article-32717.r28">[28]</xref></p>
          </list-item>
          <list-item>
            <p>Around 90%<bold>&#x000a0;</bold>of patients with multisystemic active GPA have ANCA positivity.&#x000a0;Thus,&#x000a0;an absence of ANCA does not necessarily rule out the diagnosis.</p>
          </list-item>
        </list>
        <p>
<bold>Microscopic Polyangiitis</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>MPA causes necrotizing vasculitis of small vessels without&#x000a0;granuloma formation, and it manifests commonly as glomerulonephritis that manifests with signs and symptoms of acute renal failure. Of note, kidney involvement is almost ubiquitous in MPA.</p>
          </list-item>
          <list-item>
            <p>Lung involvement in MPA is less common compared to GPA.<bold>&#x000a0;</bold>When it does occur, it typically presents as capillaritis, causing severe alveolar bleeding.&#x000a0;In addition, MPA can also cause pulmonary fibrosis.</p>
          </list-item>
          <list-item>
            <p>Around<bold>&#x000a0;</bold>90%&#x000a0;of patients&#x000a0;are ANCA-positive.</p>
          </list-item>
          <list-item>
            <p>In some cases, the disease is only limited to renal involvement without immunoglobulin and complement deposition,&#x000a0;a condition&#x000a0;sometimes called renal-limited MPA.<xref ref-type="bibr" rid="article-32717.r29">[29]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Eosinophilic Granulomatosis With Polyangiitis</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>EGPA can cause eosinophilic granulomatous lesions involving the skin, cardiac, gastrointestinal tract, and peripheral nervous system.<xref ref-type="bibr" rid="article-32717.r30">[30]</xref></p>
          </list-item>
          <list-item>
            <p>ANCA, both PR3 and MPO, have been&#x000a0;associated with variable frequencies in these patients.</p>
          </list-item>
          <list-item>
            <p>Drug-induced ANCA vasculitis</p>
          </list-item>
          <list-item>
            <p>Several medications, such as propylthiouracil, methimazole, carbimazole, hydralazine, and minocycline, have been linked to the development of ANCA-associated vasculitis.</p>
          </list-item>
          <list-item>
            <p>This drug-induced form often causes constitutional symptoms such as arthralgias, fatigue, and skin rash.</p>
          </list-item>
          <list-item>
            <p>However, the full range of clinical features, including rapidly progressive renal failure and alveolar hemorrhage, can also occur.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-32717.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>The diagnosis of vasculitis requires a high index of suspicion due to its rarity and multisystemic nature. Obtaining&#x000a0;a detailed history and performing a thorough physical examination are essential for managing vasculitis. A complete workup&#x000a0;is required to establish the diagnosis, rule out other causes, and evaluate the severity of the disease and organ involvement. To establish the diagnosis, a combination of clinical assessment with serological testing is needed, and a tissue biopsy many times confirms the diagnosis.</p>
        <p>Patients with GPA may demonstrate a C-ANCA pattern (with positive anti-PR3 antibodies) in addition to signs and symptoms of vasculitis. Although&#x000a0;typical clinical features and serology can be sufficient for diagnosis, a tissue biopsy is often performed due to the high-risk nature of the treatment.&#x000a0;A tissue biopsy of GPA shows vasculitis with necrotizing granulomas, except for a kidney biopsy, which only shows evidence of vasculitis without granulomas.<xref ref-type="bibr" rid="article-32717.r31">[31]</xref><xref ref-type="bibr" rid="article-32717.r32">[32]</xref></p>
        <p>In MPA, serology is typically positive for anti-MPO antibodies with a P-ANCA pattern in about 70% of cases, positive for PR3-ANCA in about 20% of&#x000a0;cases, and ANCA-negative in 10% of&#x000a0;cases.<xref ref-type="bibr" rid="article-32717.r12">[12]</xref></p>
        <p>In EGPA, serology is positive for MPO in about 35% of&#x000a0;cases and for anti-PR3 in about 5% of&#x000a0;cases. However, around 60% of patients are ANCA-negative.<xref ref-type="bibr" rid="article-32717.r12">[12]</xref>&#x000a0;The characteristics of EGPA&#x000a0;include&#x000a0;patients having eosinophilia in their peripheral blood and in the tissues that are affected. The absence of eosinophilia should cast doubt on the diagnosis.<xref ref-type="bibr" rid="article-32717.r33">[33]</xref></p>
        <p>In drug-induced ANCA-associated vasculitis, a detailed medication history is crucial. Many medications are linked to this condition, including propylthiouracil, methimazole, carbimazole,&#x000a0;hydralazine, minocycline, allopurinol, penicillamine, procainamide, thiamazole, clozapine, phenytoin, rifampicin, cefotaxime, isoniazid, and indomethacin.</p>
        <p>Patients should also be tested for antinuclear antibodies and anti-glomerular basement membrane antibodies, as systemic lupus erythematosus and Goodpasture syndrome (anti-glomerular basement membrane disease) can present similar clinical signs and symptoms.&#x000a0;In addition, infections such as infective endocarditis and chronic hepatitis should be excluded, as they can also mimic the presentation of vasculitis.</p>
        <p>To assess disease activity, inflammatory markers, persistence of ANCA antibodies, and kidney function (including urea and electrolytes, urine protein quantification, and urine microscopy) should be monitored. Disease activity can be tracked by clinical tools such as the Birmingham Vasculitis Activity Score (BVAS), which helps evaluate changes over time.<xref ref-type="bibr" rid="article-32717.r34">[34]</xref><xref ref-type="bibr" rid="article-32717.r35">[35]</xref></p>
      </sec>
      <sec id="article-32717.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Treatment for ANCA vasculitides typically begins with induction of remission to avoid or slow down organ involvement. The definition of remission has been standardized by the European Vasculitis Society/European League Against Rheumatism (EUVAS/EULAR) group, a no-detectable disease activity using a recognized scoring tool, such as BVAS.<xref ref-type="bibr" rid="article-32717.r36">[36]</xref></p>
        <p>Induction of remission is typically achieved with cyclophosphamide in addition to high-dose steroids. In cases with life-threatening diseases or severe kidney involvement, plasma exchange is used along with induction treatment.<xref ref-type="bibr" rid="article-32717.r37">[37]</xref><xref ref-type="bibr" rid="article-32717.r38">[38]</xref>&#x000a0;Recently, intravenous rituximab has been used for remission induction due to its fewer side effects compared to cyclophosphamide while providing the same therapeutic effect. Studies have demonstrated that rituximab has the same efficacy as cyclophosphamide in remission induction.<xref ref-type="bibr" rid="article-32717.r39">[39]</xref><xref ref-type="bibr" rid="article-32717.r40">[40]</xref>&#x000a0;In patients with disease relapse, the RAVE study (rituximab versus cyclophosphamide for ANCA-associated vasculitis) showed that rituximab is superior to cyclophosphamide. In this study, 67% of patients achieved remission at 6 months versus 42% of patients treated with cyclophosphamide.<xref ref-type="bibr" rid="article-32717.r40">[40]</xref> In some cases, methotrexate or mycophenolate mofetil may be used for remission induction, particularly in patients without evidence of organ or life-threatening disease.</p>
        <p>For maintenance of remission, rituximab is recommended. Azathioprine or methotrexate can also be considered, but&#x000a0;their use should be reserved for patients with eGFR more than 60 mL/min/1.73m<sup>2</sup>. For new-onset disease, maintenance should be continued for 24 to 48 months after the onset of remission. A longer treatment duration should be considered for patients with relapsing disease.<xref ref-type="bibr" rid="article-32717.r41">[41]</xref></p>
      </sec>
      <sec id="article-32717.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Small vessel vasculitides are classified into ANCA-associated vasculitides and immune complex vasculitides.</p>
        <p>Immune complex vasculitides can present signs and symptoms similar to ANCA-associated vasculitides, but they are distinguished histopathologically by abundant immune complex deposition in affected tissues. These conditions can be caused by infections such as hepatitis B, hepatitis C, HIV, or endocarditis. They can also be caused by autoimmune conditions such as systemic lupus erythematosus, rheumatoid arthritis, and Sj&#x000f6;gren syndrome. Cryoglobulinemia is one of the immune complex vasculitides that is caused by chronic hepatitis C infection.</p>
        <p>Antiglomerular basement membrane disease (Goodpasture syndrome) can mimic ANCA vasculitis, affecting kidneys and lungs. Approximately 10% to 40% of patients with anti-glomerular basement membrane disease test positive for ANCA (dual positivity), which indicates a higher risk of relapse.</p>
        <p>Atrial myxoma can also present with symptoms such as fatigue, fever, weight loss, purpuric skin rash, neurological involvement, and lung injury due to embolization.</p>
        <p>Malignancy rarely can mimic vasculitis, either through direct involvement of blood vessels, as observed in lymphoma, or as a paraneoplastic syndrome.<xref ref-type="bibr" rid="article-32717.r42">[42]</xref><xref ref-type="bibr" rid="article-32717.r43">[43]</xref></p>
      </sec>
      <sec id="article-32717.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The prognosis for ANCA vasculitis has significantly improved, with 1-year mortality rates decreasing from 80% to 10%, and patients now achieve prolonged remission. However, relapses remain common, particularly in patients with GPA, where recurrence occurs in more than 50% of cases within 5 years.</p>
      </sec>
      <sec id="article-32717.s12" sec-type="Complications">
        <title>Complications</title>
        <p>Complications are caused either by the disease itself or as a result of its treatment.</p>
        <p>Disease-related complications include the aforementioned manifestations and organ involvement, such as lungs, kidneys, and peripheral nerves. In addition, the patients are at increased risk for hypertension, coronary artery disease, myocardial infarction, mouth ulcers, and cerebrovascular disease.</p>
        <p>Treatment-related complications include malignancy, chemical cystitis, marrow failure, gonadal failure, diabetes, and osteoporosis.<xref ref-type="bibr" rid="article-32717.r44">[44]</xref><xref ref-type="bibr" rid="article-32717.r45">[45]</xref><xref ref-type="bibr" rid="article-32717.r46">[46]</xref></p>
      </sec>
      <sec id="article-32717.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patients should be educated about the disease, its treatment, and its adverse effects. Key educational subjects are as follows:</p>
        <p>Vasculitis refers to inflammation of the blood vessels, which can lead to vessel damage.&#x000a0;As blood vessels carry oxygen and nutrients to body tissues, their damage can harm the affected tissues.</p>
        <p>There are various types of vasculitis, some of which are medication-induced, while others occur without a known cause.</p>
        <p>Symptoms of vasculitis include fatigue, muscle pain, fever, cough, hemoptysis,&#x000a0;abdominal pain, blood in urine or weakness, and numbness in hands or feet.</p>
        <p>Treatment for vasculitis includes steroids along with other medications that suppress the immune system, such as cyclophosphamide or rituximab.</p>
      </sec>
      <sec id="article-32717.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The multisystemic nature of vasculitis, particularly ANCA-associated vasculitis, necessitates the involvement of an interprofessional healthcare team to ensure comprehensive patient care. ANCA-associated vasculitis often affects multiple organs, most notably the lungs and kidneys. The participation of rheumatologists, nephrologists, pulmonologists, pharmacologists, and nurses in patient care helps decrease the morbidity of the disease. Rheumatologists are essential for managing the overall disease process and coordinating care. Nephrologists are critical in monitoring and treating renal involvement, including rapidly progressive glomerulonephritis. Pulmonologists are vital for assessing and addressing pulmonary complications, such as alveolar hemorrhage and interstitial lung disease.</p>
        <p>Pharmacologists are essential in optimizing medication regimens and balancing the efficacy of immunosuppressive therapies with adverse effects. Nurses provide critical support in patient education, monitoring for adverse effects, and ensuring adherence to treatment plans. This coordinated approach allows for early detection of complications, personalized treatment adjustments, and overall improvement in patient outcomes, reducing the morbidity associated with vasculitis. Collaboration among these specialists enhances patient care and contributes to a more holistic approach to managing this complex disease.</p>
      </sec>
      <sec id="article-32717.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=32717&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=32717">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/health/anca-positive-vasculitis/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=32717">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/32717/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=32717">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-32717.s16">
        <title>References</title>
        <ref id="article-32717.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Falk</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Jennette</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis.</article-title>
            <source>N Engl J Med</source>
            <year>1988</year>
            <month>Jun</month>
            <day>23</day>
            <volume>318</volume>
            <issue>25</issue>
            <fpage>1651</fpage>
            <page-range>1651-7</page-range>
            <pub-id pub-id-type="pmid">2453802</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32717.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Niles</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>McCluskey</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Ahmad</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Arnaout</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Wegener's granulomatosis autoantigen is a novel neutrophil serine proteinase.</article-title>
            <source>Blood</source>
            <year>1989</year>
            <month>Nov</month>
            <day>01</day>
            <volume>74</volume>
            <issue>6</issue>
            <fpage>1888</fpage>
            <page-range>1888-93</page-range>
            <pub-id pub-id-type="pmid">2679910</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32717.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van der Woude</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Rasmussen</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Lobatto</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wiik</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Permin</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>van Es</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>van der Giessen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>van der Hem</surname>
                <given-names>GK</given-names>
              </name>
              <name>
                <surname>The</surname>
                <given-names>TH</given-names>
              </name>
            </person-group>
            <article-title>Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis.</article-title>
            <source>Lancet</source>
            <year>1985</year>
            <month>Feb</month>
            <day>23</day>
            <volume>1</volume>
            <issue>8426</issue>
            <fpage>425</fpage>
            <page-range>425-9</page-range>
            <pub-id pub-id-type="pmid">2857806</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32717.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Peters</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Saeed</surname>
                <given-names>IT</given-names>
              </name>
              <name>
                <surname>Offiah</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Jawad</surname>
                <given-names>ASM</given-names>
              </name>
            </person-group>
            <article-title>Severe localised granulomatosis with polyangiitis (Wegener's granulomatosis) manifesting with extensive cranial nerve palsies and cranial diabetes insipidus: a case report and literature review.</article-title>
            <source>BMC Neurol</source>
            <year>2018</year>
            <month>May</month>
            <day>01</day>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>59</fpage>
            <pub-id pub-id-type="pmid">29716529</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32717.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hellmich</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Sanchez-Alamo</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Schirmer</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Berti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Blockmans</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Cid</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Holle</surname>
                <given-names>JU</given-names>
              </name>
              <name>
                <surname>Hollinger</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Karadag</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Kronbichler</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Little</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Luqmani</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Mahr</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Merkel</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Mohammad</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Monti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mukhtyar</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Musial</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Price-Kuehne</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Segelmark</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Teng</surname>
                <given-names>YKO</given-names>
              </name>
              <name>
                <surname>Terrier</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Tomasson</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Vaglio</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vassilopoulos</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Verhoeven</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Jayne</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update.</article-title>
            <source>Ann Rheum Dis</source>
            <year>2024</year>
            <month>Jan</month>
            <day>02</day>
            <volume>83</volume>
            <issue>1</issue>
            <fpage>30</fpage>
            <page-range>30-47</page-range>
            <pub-id pub-id-type="pmid">36927642</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32717.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Granel</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Korkmaz</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Nouar</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Weiss</surname>
                <given-names>SAI</given-names>
              </name>
              <name>
                <surname>Jenne</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Lemoine</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hoarau</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Pathogenicity of Proteinase 3-Anti-Neutrophil Cytoplasmic Antibody in Granulomatosis With Polyangiitis: Implications as Biomarker and Future Therapies.</article-title>
            <source>Front Immunol</source>
            <year>2021</year>
            <volume>12</volume>
            <fpage>571933</fpage>
            <pub-id pub-id-type="pmid">33679731</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32717.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Xie</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Liang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Clinical features and outcomes of patients with antineutrophil cytoplasmic antibody-positive systemic lupus erythematosus.</article-title>
            <source>Ren Fail</source>
            <year>2023</year>
            <month>Dec</month>
            <volume>45</volume>
            <issue>1</issue>
            <fpage>2235431</fpage>
            <pub-id pub-id-type="pmid">37470370</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32717.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Radice</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sinico</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Antineutrophil cytoplasmic antibodies (ANCA).</article-title>
            <source>Autoimmunity</source>
            <year>2005</year>
            <month>Feb</month>
            <volume>38</volume>
            <issue>1</issue>
            <fpage>93</fpage>
            <page-range>93-103</page-range>
            <pub-id pub-id-type="pmid">15804710</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32717.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ntatsaki</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Watts</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Scott</surname>
                <given-names>DG</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology of ANCA-associated vasculitis.</article-title>
            <source>Rheum Dis Clin North Am</source>
            <year>2010</year>
            <month>Aug</month>
            <volume>36</volume>
            <issue>3</issue>
            <fpage>447</fpage>
            <page-range>447-61</page-range>
            <pub-id pub-id-type="pmid">20688243</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32717.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Iudici</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Quartier</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Terrier</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Mouthon</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Guillevin</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Pu&#x000e9;chal</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Childhood-onset granulomatosis with polyangiitis and microscopic polyangiitis: systematic review and meta-analysis.</article-title>
            <source>Orphanet J Rare Dis</source>
            <year>2016</year>
            <month>Oct</month>
            <day>22</day>
            <volume>11</volume>
            <issue>1</issue>
            <fpage>141</fpage>
            <pub-id pub-id-type="pmid">27770813</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32717.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dirikgil</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Jonker</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Tas</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Verburgh</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Soonawala</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hak</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Remmelts</surname>
                <given-names>HHF</given-names>
              </name>
              <name>
                <surname>IJpelaar</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Laverman</surname>
                <given-names>GD</given-names>
              </name>
              <name>
                <surname>Rutgers</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>van Laar</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Moen</surname>
                <given-names>HJB</given-names>
              </name>
              <name>
                <surname>Verhoeven</surname>
                <given-names>PMJ</given-names>
              </name>
              <name>
                <surname>Rabelink</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Bos</surname>
                <given-names>WJW</given-names>
              </name>
              <name>
                <surname>Teng</surname>
                <given-names>YKO</given-names>
              </name>
              <collab>Arthritis Research &#x00026; Collaboration Hub (ARCH) study group</collab>
            </person-group>
            <article-title>Clinical Practice Audit on the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis in the Netherlands.</article-title>
            <source>Kidney Int Rep</source>
            <year>2021</year>
            <month>Oct</month>
            <volume>6</volume>
            <issue>10</issue>
            <fpage>2671</fpage>
            <page-range>2671-2678</page-range>
            <pub-id pub-id-type="pmid">34622106</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32717.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Walulik</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>&#x00141;ysak</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>B&#x00142;aszkiewicz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>G&#x000f3;recki</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Gomu&#x00142;ka</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>The Role of Neutrophils in ANCA-Associated Vasculitis: The Pathogenic Role and Diagnostic Utility of Autoantibodies.</article-title>
            <source>Int J Mol Sci</source>
            <year>2023</year>
            <month>Dec</month>
            <day>07</day>
            <volume>24</volume>
            <issue>24</issue>
            <pub-id pub-id-type="pmid">38139045</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32717.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cartin-Ceba</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Peikert</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Specks</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>Pathogenesis of ANCA-associated vasculitis.</article-title>
            <source>Curr Rheumatol Rep</source>
            <year>2012</year>
            <month>Dec</month>
            <volume>14</volume>
            <issue>6</issue>
            <fpage>481</fpage>
            <page-range>481-93</page-range>
            <pub-id pub-id-type="pmid">22927039</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32717.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kessenbrock</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Krumbholz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sch&#x000f6;nermarck</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Back</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Gross</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>Werb</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Gr&#x000f6;ne</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Brinkmann</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Jenne</surname>
                <given-names>DE</given-names>
              </name>
            </person-group>
            <article-title>Netting neutrophils in autoimmune small-vessel vasculitis.</article-title>
            <source>Nat Med</source>
            <year>2009</year>
            <month>Jun</month>
            <volume>15</volume>
            <issue>6</issue>
            <fpage>623</fpage>
            <page-range>623-5</page-range>
            <pub-id pub-id-type="pmid">19448636</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32717.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Walsh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Merkel</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Peh</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Szpirt</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Guillevin</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Pusey</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>De Zoysa</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ives</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>WF</given-names>
              </name>
              <name>
                <surname>Quillen</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Winters</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Wheatley</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Jayne</surname>
                <given-names>D</given-names>
              </name>
              <collab>PEXIVAS Investigators</collab>
            </person-group>
            <article-title>Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial.</article-title>
            <source>Trials</source>
            <year>2013</year>
            <month>Mar</month>
            <day>14</day>
            <volume>14</volume>
            <fpage>73</fpage>
            <pub-id pub-id-type="pmid">23497590</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32717.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Papiha</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Murty</surname>
                <given-names>GE</given-names>
              </name>
              <name>
                <surname>Ad'Hia</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mains</surname>
                <given-names>BT</given-names>
              </name>
              <name>
                <surname>Venning</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Association of Wegener's granulomatosis with HLA antigens and other genetic markers.</article-title>
            <source>Ann Rheum Dis</source>
            <year>1992</year>
            <month>Feb</month>
            <volume>51</volume>
            <issue>2</issue>
            <fpage>246</fpage>
            <page-range>246-8</page-range>
            <pub-id pub-id-type="pmid">1550412</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32717.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nikkari</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mertsola</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Korvenranta</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Vainionp&#x000e4;&#x000e4;</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Toivanen</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Wegener's granulomatosis and parvovirus B19 infection.</article-title>
            <source>Arthritis Rheum</source>
            <year>1994</year>
            <month>Nov</month>
            <volume>37</volume>
            <issue>11</issue>
            <fpage>1707</fpage>
            <page-range>1707-8</page-range>
            <pub-id pub-id-type="pmid">7980681</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32717.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hogan</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Markowitz</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Radhakrishnan</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Drug-induced glomerular disease: immune-mediated injury.</article-title>
            <source>Clin J Am Soc Nephrol</source>
            <year>2015</year>
            <month>Jul</month>
            <day>07</day>
            <volume>10</volume>
            <issue>7</issue>
            <fpage>1300</fpage>
            <page-range>1300-10</page-range>
            <pub-id pub-id-type="pmid">26092827</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32717.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Anguiano</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kain</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Anders</surname>
                <given-names>HJ</given-names>
              </name>
            </person-group>
            <article-title>The glomerular crescent: triggers, evolution, resolution, and implications for therapy.</article-title>
            <source>Curr Opin Nephrol Hypertens</source>
            <year>2020</year>
            <month>May</month>
            <volume>29</volume>
            <issue>3</issue>
            <fpage>302</fpage>
            <page-range>302-309</page-range>
            <pub-id pub-id-type="pmid">32132388</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32717.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arimura</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Muso</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Fujimoto</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hasegawa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kaname</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Usui</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ihara</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kobayashi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Itabashi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kitagawa</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hirahashi</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kimura</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Matsuo</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Evidence-based clinical practice guidelines for rapidly progressive glomerulonephritis 2014.</article-title>
            <source>Clin Exp Nephrol</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>20</volume>
            <issue>3</issue>
            <fpage>322</fpage>
            <page-range>322-41</page-range>
            <pub-id pub-id-type="pmid">27099135</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32717.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pacheco</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Silva</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Silva</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Soares</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Almeida</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Double-Positive Anti-GBM and ANCA-MPO Vasculitis Presenting With Crescentic Glomerulonephritis.</article-title>
            <source>Cureus</source>
            <year>2021</year>
            <month>May</month>
            <day>02</day>
            <volume>13</volume>
            <issue>5</issue>
            <fpage>e14806</fpage>
            <pub-id pub-id-type="pmid">34094762</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32717.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Clerte</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Philip</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Levi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cornec-Le Gall</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Audard</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Huart</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pu&#x000e9;chal</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Touzot</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rabot</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Thervet</surname>
                <given-names>&#x000c9;</given-names>
              </name>
              <name>
                <surname>Aouba</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Karras</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Renal and overall outcomes of double-positive (ANCA and anti-GBM antibodies) patients compared to ANCA-associated vasculitis patients with severe renal involvement: A multicenter retrospective study with systematic renal pathology analysis.</article-title>
            <source>Scand J Rheumatol</source>
            <year>2022</year>
            <month>May</month>
            <volume>51</volume>
            <issue>3</issue>
            <fpage>205</fpage>
            <page-range>205-213</page-range>
            <pub-id pub-id-type="pmid">34169779</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32717.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jennette</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Falk</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Bacon</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Basu</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Cid</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Ferrario</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Flores-Suarez</surname>
                <given-names>LF</given-names>
              </name>
              <name>
                <surname>Gross</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>Guillevin</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hagen</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Hoffman</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Jayne</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Kallenberg</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Lamprecht</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Langford</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Luqmani</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Mahr</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Matteson</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Merkel</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Ozen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pusey</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Rasmussen</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Rees</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Scott</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Specks</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Stone</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Takahashi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Watts</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides.</article-title>
            <source>Arthritis Rheum</source>
            <year>2013</year>
            <month>Jan</month>
            <volume>65</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-11</page-range>
            <pub-id pub-id-type="pmid">23045170</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32717.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Holl-Ulrich</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>[Histopathology of systemic vasculitis].</article-title>
            <source>Pathologe</source>
            <year>2010</year>
            <month>Feb</month>
            <volume>31</volume>
            <issue>1</issue>
            <fpage>67</fpage>
            <page-range>67-76</page-range>
            <pub-id pub-id-type="pmid">19533137</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32717.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jennette</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Falk</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Pathogenesis of antineutrophil cytoplasmic autoantibody-mediated disease.</article-title>
            <source>Nat Rev Rheumatol</source>
            <year>2014</year>
            <month>Aug</month>
            <volume>10</volume>
            <issue>8</issue>
            <fpage>463</fpage>
            <page-range>463-73</page-range>
            <pub-id pub-id-type="pmid">25003769</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32717.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Comarmond</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cacoub</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Granulomatosis with polyangiitis (Wegener): clinical aspects and treatment.</article-title>
            <source>Autoimmun Rev</source>
            <year>2014</year>
            <month>Nov</month>
            <volume>13</volume>
            <issue>11</issue>
            <fpage>1121</fpage>
            <page-range>1121-5</page-range>
            <pub-id pub-id-type="pmid">25149391</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32717.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Daum</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Specks</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Colby</surname>
                <given-names>TV</given-names>
              </name>
              <name>
                <surname>Edell</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Brutinel</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Prakash</surname>
                <given-names>UB</given-names>
              </name>
              <name>
                <surname>DeRemee</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Tracheobronchial involvement in Wegener's granulomatosis.</article-title>
            <source>Am J Respir Crit Care Med</source>
            <year>1995</year>
            <month>Feb</month>
            <volume>151</volume>
            <issue>2 Pt 1</issue>
            <fpage>522</fpage>
            <page-range>522-6</page-range>
            <pub-id pub-id-type="pmid">7842215</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32717.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chang</surname>
                <given-names>DY</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kallenberg</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>MH</given-names>
              </name>
            </person-group>
            <article-title>Re-evaluation of the histopathologic classification of ANCA-associated glomerulonephritis: a study of 121 patients in a single center.</article-title>
            <source>Nephrol Dial Transplant</source>
            <year>2012</year>
            <month>Jun</month>
            <volume>27</volume>
            <issue>6</issue>
            <fpage>2343</fpage>
            <page-range>2343-9</page-range>
            <pub-id pub-id-type="pmid">22121235</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32717.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kallenberg</surname>
                <given-names>CG</given-names>
              </name>
            </person-group>
            <article-title>The diagnosis and classification of microscopic polyangiitis.</article-title>
            <source>J Autoimmun</source>
            <year>2014</year>
            <season>Feb-Mar</season>
            <volume>48-49</volume>
            <fpage>90</fpage>
            <page-range>90-3</page-range>
            <pub-id pub-id-type="pmid">24461388</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32717.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mouthon</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Dunogue</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Guillevin</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and classification of eosinophilic granulomatosis with polyangiitis (formerly named Churg-Strauss syndrome).</article-title>
            <source>J Autoimmun</source>
            <year>2014</year>
            <season>Feb-Mar</season>
            <volume>48-49</volume>
            <fpage>99</fpage>
            <page-range>99-103</page-range>
            <pub-id pub-id-type="pmid">24530234</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32717.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van der Geest</surname>
                <given-names>KSM</given-names>
              </name>
              <name>
                <surname>Brouwer</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Sanders</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Sandovici</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bos</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Boots</surname>
                <given-names>AMH</given-names>
              </name>
              <name>
                <surname>Abdulahad</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Stegeman</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Kallenberg</surname>
                <given-names>CGM</given-names>
              </name>
              <name>
                <surname>Heeringa</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Rutgers</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Towards precision medicine in ANCA-associated vasculitis.</article-title>
            <source>Rheumatology (Oxford)</source>
            <year>2018</year>
            <month>Aug</month>
            <day>01</day>
            <volume>57</volume>
            <issue>8</issue>
            <fpage>1332</fpage>
            <page-range>1332-1339</page-range>
            <pub-id pub-id-type="pmid">29045715</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32717.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cornec</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Cornec-Le Gall</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Fervenza</surname>
                <given-names>FC</given-names>
              </name>
              <name>
                <surname>Specks</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>ANCA-associated vasculitis - clinical utility of using ANCA specificity to classify patients.</article-title>
            <source>Nat Rev Rheumatol</source>
            <year>2016</year>
            <month>Oct</month>
            <volume>12</volume>
            <issue>10</issue>
            <fpage>570</fpage>
            <page-range>570-9</page-range>
            <pub-id pub-id-type="pmid">27464484</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32717.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Franssen</surname>
                <given-names>CF</given-names>
              </name>
              <name>
                <surname>Huitema</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Muller Kobold</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Oost-Kort</surname>
                <given-names>WW</given-names>
              </name>
              <name>
                <surname>Limburg</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Tiebosch</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Stegeman</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Kallenberg</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Tervaert</surname>
                <given-names>JW</given-names>
              </name>
            </person-group>
            <article-title>In vitro neutrophil activation by antibodies to proteinase 3 and myeloperoxidase from patients with crescentic glomerulonephritis.</article-title>
            <source>J Am Soc Nephrol</source>
            <year>1999</year>
            <month>Jul</month>
            <volume>10</volume>
            <issue>7</issue>
            <fpage>1506</fpage>
            <page-range>1506-15</page-range>
            <pub-id pub-id-type="pmid">10405206</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32717.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mukhtyar</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Carruthers</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Dasgupta</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Dubey</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Flossmann</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Hall</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hollywood</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jayne</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lanyon</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Muir</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Scott</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Luqmani</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Modification and validation of the Birmingham Vasculitis Activity Score (version 3).</article-title>
            <source>Ann Rheum Dis</source>
            <year>2009</year>
            <month>Dec</month>
            <volume>68</volume>
            <issue>12</issue>
            <fpage>1827</fpage>
            <page-range>1827-32</page-range>
            <pub-id pub-id-type="pmid">19054820</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32717.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Koh</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Kemna</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Cohen Tervaert</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>WU</given-names>
              </name>
            </person-group>
            <article-title>Editorial: Can an Increase in Antineutrophil Cytoplasmic Autoantibody Titer Predict Relapses in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis?</article-title>
            <source>Arthritis Rheumatol</source>
            <year>2016</year>
            <month>Jul</month>
            <volume>68</volume>
            <issue>7</issue>
            <fpage>1571</fpage>
            <page-range>1571-3</page-range>
            <pub-id pub-id-type="pmid">26882278</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32717.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hellmich</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Flossmann</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Gross</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>Bacon</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Cohen-Tervaert</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Guillevin</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Jayne</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mahr</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Merkel</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Raspe</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Scott</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Witter</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yazici</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Luqmani</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis.</article-title>
            <source>Ann Rheum Dis</source>
            <year>2007</year>
            <month>May</month>
            <volume>66</volume>
            <issue>5</issue>
            <fpage>605</fpage>
            <page-range>605-17</page-range>
            <pub-id pub-id-type="pmid">17170053</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32717.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Harper</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Morgan</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Walsh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hoglund</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Westman</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Flossmann</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Tesar</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Vanhille</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>de Groot</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Luqmani</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Flores-Suarez</surname>
                <given-names>LF</given-names>
              </name>
              <name>
                <surname>Watts</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pusey</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bruchfeld</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rasmussen</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Blockmans</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Savage</surname>
                <given-names>CO</given-names>
              </name>
              <name>
                <surname>Jayne</surname>
                <given-names>D</given-names>
              </name>
              <collab>EUVAS investigators</collab>
            </person-group>
            <article-title>Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up.</article-title>
            <source>Ann Rheum Dis</source>
            <year>2012</year>
            <month>Jun</month>
            <volume>71</volume>
            <issue>6</issue>
            <fpage>955</fpage>
            <page-range>955-60</page-range>
            <pub-id pub-id-type="pmid">22128076</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32717.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ntatsaki</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Carruthers</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Chakravarty</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>D'Cruz</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Harper</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Jayne</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Luqmani</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mills</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mooney</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Venning</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Watts</surname>
                <given-names>RA</given-names>
              </name>
              <collab>BSR and BHPR Standards, Guidelines and Audit Working Group</collab>
            </person-group>
            <article-title>BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis.</article-title>
            <source>Rheumatology (Oxford)</source>
            <year>2014</year>
            <month>Dec</month>
            <volume>53</volume>
            <issue>12</issue>
            <fpage>2306</fpage>
            <page-range>2306-9</page-range>
            <pub-id pub-id-type="pmid">24729399</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32717.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jones</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Tervaert</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Hauser</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Luqmani</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Morgan</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Peh</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Savage</surname>
                <given-names>CO</given-names>
              </name>
              <name>
                <surname>Segelmark</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tesar</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>van Paassen</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Walsh</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Walsh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Westman</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Jayne</surname>
                <given-names>DR</given-names>
              </name>
              <collab>European Vasculitis Study Group</collab>
            </person-group>
            <article-title>Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.</article-title>
            <source>N Engl J Med</source>
            <year>2010</year>
            <month>Jul</month>
            <day>15</day>
            <volume>363</volume>
            <issue>3</issue>
            <fpage>211</fpage>
            <page-range>211-20</page-range>
            <pub-id pub-id-type="pmid">20647198</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32717.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stone</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Merkel</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Spiera</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Seo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Langford</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Hoffman</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Kallenberg</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>St Clair</surname>
                <given-names>EW</given-names>
              </name>
              <name>
                <surname>Turkiewicz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tchao</surname>
                <given-names>NK</given-names>
              </name>
              <name>
                <surname>Webber</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ding</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sejismundo</surname>
                <given-names>LP</given-names>
              </name>
              <name>
                <surname>Mieras</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Weitzenkamp</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ikle</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Seyfert-Margolis</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Mueller</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Brunetta</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Allen</surname>
                <given-names>NB</given-names>
              </name>
              <name>
                <surname>Fervenza</surname>
                <given-names>FC</given-names>
              </name>
              <name>
                <surname>Geetha</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Keogh</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Kissin</surname>
                <given-names>EY</given-names>
              </name>
              <name>
                <surname>Monach</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Peikert</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Stegeman</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ytterberg</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Specks</surname>
                <given-names>U</given-names>
              </name>
              <collab>RAVE-ITN Research Group</collab>
            </person-group>
            <article-title>Rituximab versus cyclophosphamide for ANCA-associated vasculitis.</article-title>
            <source>N Engl J Med</source>
            <year>2010</year>
            <month>Jul</month>
            <day>15</day>
            <volume>363</volume>
            <issue>3</issue>
            <fpage>221</fpage>
            <page-range>221-32</page-range>
            <pub-id pub-id-type="pmid">20647199</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32717.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Casal Moura</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gauckler</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Anders</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Bruchfeld</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fernandez-Juarez</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Floege</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Frangou</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Goumenos</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Segelmark</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Turkmen</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>van Kooten</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tesar</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Geetha</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Fervenza</surname>
                <given-names>FC</given-names>
              </name>
              <name>
                <surname>Jayne</surname>
                <given-names>DRW</given-names>
              </name>
              <name>
                <surname>Stevens</surname>
                <given-names>KI</given-names>
              </name>
              <name>
                <surname>Kronbichler</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Management of antineutrophil cytoplasmic antibody-associated vasculitis with glomerulonephritis as proposed by the ACR 2021, EULAR 2022 and KDIGO 2021 guidelines/recommendations.</article-title>
            <source>Nephrol Dial Transplant</source>
            <year>2023</year>
            <month>Oct</month>
            <day>31</day>
            <volume>38</volume>
            <issue>11</issue>
            <fpage>2637</fpage>
            <page-range>2637-2651</page-range>
            <pub-id pub-id-type="pmid">37164940</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32717.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>STORCK</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>[Hemorrhagic phenomena in dermatology].</article-title>
            <source>Dermatologica</source>
            <year>1951</year>
            <volume>102</volume>
            <issue>4-6</issue>
            <fpage>197</fpage>
            <page-range>197-252</page-range>
            <pub-id pub-id-type="pmid">14849252</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32717.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Agnello</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Romain</surname>
                <given-names>PL</given-names>
              </name>
            </person-group>
            <article-title>Mixed cryoglobulinemia secondary to hepatitis C virus infection.</article-title>
            <source>Rheum Dis Clin North Am</source>
            <year>1996</year>
            <month>Feb</month>
            <volume>22</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-21</page-range>
            <pub-id pub-id-type="pmid">8907062</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32717.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Robson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Doll</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Suppiah</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Flossmann</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Harper</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>H&#x000f6;glund</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Jayne</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mahr</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Westman</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Luqmani</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Damage in the anca-associated vasculitides: long-term data from the European vasculitis study group (EUVAS) therapeutic trials.</article-title>
            <source>Ann Rheum Dis</source>
            <year>2015</year>
            <month>Jan</month>
            <volume>74</volume>
            <issue>1</issue>
            <fpage>177</fpage>
            <page-range>177-84</page-range>
            <pub-id pub-id-type="pmid">24243925</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32717.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Exley</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Bacon</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Luqmani</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Kitas</surname>
                <given-names>GD</given-names>
              </name>
              <name>
                <surname>Carruthers</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Moots</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Examination of disease severity in systemic vasculitis from the novel perspective of damage using the vasculitis damage index (VDI).</article-title>
            <source>Br J Rheumatol</source>
            <year>1998</year>
            <month>Jan</month>
            <volume>37</volume>
            <issue>1</issue>
            <fpage>57</fpage>
            <page-range>57-63</page-range>
            <pub-id pub-id-type="pmid">9487252</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32717.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Koldingsnes</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Nossent</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Predictors of survival and organ damage in Wegener's granulomatosis.</article-title>
            <source>Rheumatology (Oxford)</source>
            <year>2002</year>
            <month>May</month>
            <volume>41</volume>
            <issue>5</issue>
            <fpage>572</fpage>
            <page-range>572-81</page-range>
            <pub-id pub-id-type="pmid">12011383</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
